ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California. Its pipeline is centered on evorpacept (ALX148), a CD47 blocker designed to enhance macrophage-mediated tumor cell clearance while aiming to avoid hematologic toxicities seen with other CD47 approaches. The company is also advancing ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) built from an in-house linker-payload platform, which entered first-in-human Phase 1 dosing in 2025. ALX Oncology has no products approved for marketing and has not generated revenue from product sales, with operations focused on R&D, clinical trials, and manufacturing scale-up for clinical supply.
2.07
2.07
| % | |
|---|---|
| Evorpacept (CD47 blocker) program | 65% Clinical development of evorpacept across Phase 1/2 studies, including combination regimens with targeted antibodies and chemotherapy. |
| ALX2004 (EGFR ADC) program | 20% First-in-human clinical development of an EGFR-targeted ADC using an in-house antibody and proprietary linker-payload design. |
| Early pipeline & collaborations (e.g., ALTA-002) | 10% Earlier-stage programs including partnered assets such as ALTA-002 (TRAAC) combining a SIRPα antibody with a TLR9 agonist. |
| Platform and enabling capabilities | 5% R&D and CMC capabilities supporting antibody engineering, linker-payload development, and clinical supply manufacturing scale-up. |
ALX Oncology is not yet commercial and therefore does not have traditional product customers; its near-term "customers"...
Administer evorpacept and ALX2004 under protocols; critical for enrollment, safety monitoring, and data generation.
Academic institutions sponsor studies (e.g., UC San Diego) to explore new combinations/indications that can expand clinical evidence.
Oncologists and infusion centers would adopt therapies based on efficacy/safety and guideline placement if approvals are obtained.
Public and private payors would influence access via coverage, prior authorization, and rebate/price reporting requirements post-approval.
ALX Oncology is headquartered in South San Francisco, California and operates primarily through U.S...
The company’s strategy is to advance evorpacept as a next-generation CD47 checkpoint inhibitor positioned for...
Clinical efficacy and safety data in defined tumor settings drive partnering, pivotal trial design, and eventual approval prospects.
A differentiated ADC platform can create multiple follow-on candidates and diversify dependence on a single asset.
Partnered programs can broaden immuno-oncology approaches while sharing scientific and development risk.
ALX Oncology faces binary clinical development risk because its value is concentrated in investigational assets,...
The company is substantially dependent on its lead candidate, which remains in clinical development and has not completed a pivotal trial.
The company has incurred significant net losses, expects continued losses, and will require substantial additional capital that may not be available on favorable terms.
Newly approved therapeutics in immuno-oncology could change treatment paradigms, negatively impacting trial design and prospects for evorpacept and ALX2004.
Disruptions at the FDA or other agencies could hinder timely review and approval activities on which development depends.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
ELVN · Pharmaceutical Preparations
: 11/08/2026